Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lumos Pharma Inc
(NQ:
LUMO
)
3.010
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lumos Pharma Inc
< Previous
1
2
3
4
Next >
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 15, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
August 01, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
July 23, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma: Q4 Earnings Insights
March 07, 2024
Via
Benzinga
Earnings Preview: Lumos Pharma
March 06, 2024
Via
Benzinga
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
June 04, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
May 20, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024
May 14, 2024
LUMO stock results show that Lumos Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
May 14, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
May 09, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
April 18, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate
March 25, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
March 20, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023
March 07, 2024
LUMO stock results show that Lumos Pharma missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
March 07, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
February 26, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
February 05, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 7, 2024
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via
Benzinga
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
January 04, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
November 21, 2023
Webinar to be Held December 6, 2023 at 1:30pm EST
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
November 20, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Why Toast Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 08, 2023
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares climbed 96% to $0.2921 after falling over 7% on Tuesday.
Via
Benzinga
Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today?
November 08, 2023
Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial met all...
Via
Benzinga
Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday
November 08, 2023
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 08, 2023
Via
Benzinga
Why American Public Education Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
November 08, 2023
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 332% to $0.6455 in pre-market trading after falling over 7% on Tuesday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 08, 2023
Pre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones.
Via
InvestorPlace
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
November 07, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 07, 2023
Via
Benzinga
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
November 07, 2023
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3
From
Lumos Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.